Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin DPI intermittent dosing in adults with non-cystic fibrosis bronchiectasis
2013-004659-19Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ciprofloxacin in bronchiectasis (3 arms), sponsored by Bayer. Primary endpoints: Time to first pulmonary exacerbation requiring systemic antibiotics and Frequency of pulmonary exacerbations requiring systemic antibiotics. Started Feb 2014; status: completed.
02
Drugs
ciprofloxacin
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2013-004659-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004659-19.